Brigg Siobhan Ernan, Koekemoer Lizbé, Brand Leisl A, Strauss Erick
Department of Biochemistry, Stellenbosch University, Matieland, 7602, South Africa.
ChemMedChem. 2023 Apr 3;18(7):e202200630. doi: 10.1002/cmdc.202200630. Epub 2023 Feb 22.
The research and development of a new antimicrobial drug using a target-based approach raises the question of whether any resulting hits will also show activity against the homologous target in other closely related organisms. While an assessment of the similarities of the predicted interactions between the identified inhibitor and the various targets is an obvious first step in answering this question, no clear and consistent framework has been proposed for how this should be done. Here we developed Multifaceted Target Specificity Analysis (MTSA) and applied it to type III pantothenate kinase (PanK ) - an essential enzyme required for coenzyme A biosynthesis in a wide range of pathogenic bacteria - as a case study to establish if targeting a specific organism's PanK would lead to a narrow- or broad-spectrum agent. We propose that MTSA is a useful tool and aid for directing new target-based antimicrobial drug development initiatives.
采用基于靶点的方法研发新型抗菌药物,引发了这样一个问题:由此产生的任何活性化合物是否也会对其他密切相关生物体中的同源靶点显示出活性。虽然评估已鉴定抑制剂与各种靶点之间预测相互作用的相似性显然是回答这个问题的第一步,但对于应该如何进行评估,尚未提出明确且一致的框架。在此,我们开发了多方面靶点特异性分析(MTSA),并将其应用于III型泛酸激酶(PanK)——多种致病细菌中辅酶A生物合成所需的一种必需酶——作为案例研究,以确定靶向特定生物体的PanK是否会产生窄谱或广谱药物。我们认为MTSA是指导基于新靶点的抗菌药物研发计划的有用工具和辅助手段。